Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

Corcept Therapeutics (NASDAQ:CORT) said on Thursday that the mid-stage study of its cortisol modulator, dazucorilant, in ...

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

H.C. Wainwright analysts on Tuesday maintained their $145 price target and Buy rating for Corcept Therapeutics Incorporated ...

We are working with regulatory authorities to determine the optimal path for advancing dazucorilant,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We would like to thank ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ...

Corcept is a profitable midcap biotechnology company specializing in treating Cushing's Syndrome, with significant potential for revenue growth and expansion into other therapeutic areas.

Company's shares hit all-time high after trial success Corcept plans to file US marketing application in third quarter Drug relacorilant may get broader label than competitors, analyst says March ...

Corcept Therapeutics Inc. shares CORT dropped 32% premarket on Tuesday after a federal court in New Jersey on Friday ruled against the drugmaker in its patent infringement lawsuit against Teva ...